OMNICELL, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OMNICELL, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $787.31M | Feb 27, 2019 |
| FY2018 | Dec 31, 2017 | $712.71M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $695.91M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $484.56M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $440.90M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $380.59M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $314.03M | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | $245.54M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $222.41M | Mar 11, 2013 |
| FY2011 | Dec 31, 2009 | $213.46M | Mar 8, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.18B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.11B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.15B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.30B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.13B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $892.21M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $897.03M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $787.31M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $712.71M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $695.91M | Feb 27, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $716.17M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $692.62M | Feb 27, 2018 |
| FY2017 | Dec 31, 2015 | $484.56M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $440.90M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $380.59M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $314.03M | Mar 30, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $503.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $471.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $496.84M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $588.99M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $554.65M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $413.29M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $436.91M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $372.33M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $318.64M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $317.09M | Feb 27, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.53M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($20.37M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $5.65M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $77.85M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $32.19M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $61.34M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $37.73M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $30.52M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $9.76M | Feb 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $337.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($34.87M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($2.32M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $89.51M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $35.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $78.35M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $44.39M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $11.15M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $21.41M | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $90.41M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $97.12M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $104.97M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $75.72M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $70.16M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $68.64M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $64.84M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $66.02M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $57.80M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $380.25M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $434.59M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $486.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $389.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $307.61M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $289.92M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $263.10M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $241.47M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $237.88M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $187.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $181.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $77.78M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $231.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $185.87M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $145.01M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $103.97M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $24.83M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $49.90M | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $36.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $41.47M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $47.54M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $28.97M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $22.84M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $15.89M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $23.70M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $15.34M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $13.45M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.97B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.12B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.23B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.21B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.14B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.82B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.24B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.08B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $1.02B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $935.10M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $742.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $877.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.08B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $995.81M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $857.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $395.56M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $401.63M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $462.02M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $503.50M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.24B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.19B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $1.13B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $1.15B | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $967.50M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $845.25M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $679.62M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $554.34M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $458.84M | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $737.95M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $734.73M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $735.81M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $734.27M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $738.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $499.31M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $336.54M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $335.89M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $337.75M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $327.72M | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $384.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $382.89M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $370.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $390.73M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $368.57M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $290.72M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $258.79M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $197.45M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $159.73M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $100.40M | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $369.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $467.97M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $330.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $349.05M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $485.93M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $127.21M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $67.19M | Feb 24, 2021 |
| FY2018 | Dec 31, 2017 | $32.42M | Feb 27, 2019 |
| FY2018 | Dec 31, 2016 | $54.49M | Feb 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $50.00M | Feb 26, 2020 |
| FY2019 | Dec 31, 2018 | $140.00M | Feb 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 27, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Feb 27, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45.03M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 46.38M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 45.54M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 44.75M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 44.18M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 42.78M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 42.13M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 40.34M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 38.43M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 36.63M | Feb 27, 2018 |